

Please try another search
For the three months ended 31 March 2022, Eagle Pharmaceuticals Inc revenues increased from $41.2M to $115.9M. Net income totaled $44.1M vs. loss of $421K. Revenues reflect Product sales increase from $17.1M to $90.1M, Royalty revenue increase of 7% to $25.8M. Net Income reflects Research and development - Balancing decrease of 59% to $5.5M (expense), Stock-based Compensation in SGA decrease of 35% to $3.7M (expense).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 115.87 | 42.32 | 39.85 | 48.12 |
Gross Profit | 88.12 | 30.01 | 31.59 | 37.37 |
Operating Income | 59.83 | 5.9 | -10.18 | 10.82 |
Net Income | 44.06 | -6.2 | -5.62 | 3.61 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 320.17 | 253.73 | 256.26 | 264.24 |
Total Liabilities | 104.2 | 77.28 | 70.97 | 69.39 |
Total Equity | 215.96 | 176.45 | 185.29 | 194.85 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -16.61 | 28.22 | 20.14 | 19.07 |
Cash From Investing Activities | -0.17 | -5.32 | -5.27 | -5.27 |
Cash From Financing Activities | -11.36 | -28.39 | -18.28 | -8.24 |
Net Change in Cash | -28.14 | -5.5 | -3.41 | 5.56 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review